{"id":172125,"name":"BRAEBURN PHARMACEUTICALS, INC.","slug":"braeburn-pharmaceuticals-inc","state":"NJ","country":"United States of America","description":"pharmaceutical company","totalSpending":1400000,"filings":32,"yearlySpending":[{"year":2018,"income":250000},{"year":2019,"income":200000},{"year":2020,"income":200000},{"year":2021,"income":200000},{"year":2022,"income":5000},{"year":2023,"income":160000},{"year":2024,"income":185000},{"year":2025,"income":200000}],"issues":["HCR"],"firms":["STANTON PARK GROUP"],"lobbyists":["JAMES DERDERIAN","ERIN STRAWN","VALERIE HENRY","EMILY SHETTY","SARAH HAMLETT","JOSEPH RACHINSKY","ANDREA BERGMAN","BRYAN WELLS","AISLING MCDONOUGH"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","Office of Natl Drug Control Policy (NDCP)","SENATE","Substance Abuse & Mental Health Services Administration (SAMHSA)","White House Office","Food & Drug Administration (FDA)"],"sampleDescriptions":["reducing stigma and promoting treatment of opioid use disorder\nraising awareness of the benefits of medication assisted therapy (MAT)\nensuring patient access to MAT, including S.916- Protecting Patien","reducing stigma and promoting treatment of opioid use disorder\nraising awareness of the benefits of medication assisted therapy (MAT)\nensuring patient access to MAT, including S.916- Protecting Patien","reducing stigma and promoting treatment of opioid use disorder\nraising awareness of the benefits of medication assisted therapy (MAT)\nensuring patient access to MAT, including S.916- Protecting Patien","reducing stigma and promoting treatment of opioid use disorder\nraising awareness of the benefits of medication assisted therapy (MAT)\nensuring patient access to MAT, including S.916- Protecting Patien","reducing stigma and promoting treatment of opioid use disorder\nraising awareness of the benefits of medication assisted therapy (MAT)\nensuring patient access to MAT, including S.916- Protecting Patien"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}